Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules

Imeglimin is a new anti-diabetic drug commercialized in Japan (Twymeeg®) and has been drawing much attention in diabetes research area as well as in clinical practice. In this study, we evaluated the effect of imeglimin on pancreatic β-cells. First, single-dose administration of imeglimin enhanced i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanada, Junpei, Obata, Atsushi, Fushimi, Yoshiro, Kimura, Tomohiko, Shimoda, Masashi, Ikeda, Tomoko, Nogami, Yuka, Obata, Yoshiyuki, Yamasaki, Yuki, Nakanishi, Shuhei, Mune, Tomoatsu, Kaku, Kohei, Kaneto, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345869/
https://www.ncbi.nlm.nih.gov/pubmed/35918386
http://dx.doi.org/10.1038/s41598-022-17657-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345869/
https://www.ncbi.nlm.nih.gov/pubmed/35918386
http://dx.doi.org/10.1038/s41598-022-17657-3

Ejemplares similares